Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Chordoma × Tiragolumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Rhabdoid Tumor 1 Glioblastoma 1 Colorectal Neoplasms 1 Chordoma 1 Advanced Rare Malignant Solid Neoplasm 1

Interventions

Specimen Handling 2 Magnetic Resonance Spectroscopy 2 atezolizumab 1 X-Rays 1 Tiragolumab 1 Phantoms, Imaging 1 Nivolumab 1 Ipilimumab 1 Gelclair 1 Fluorodeoxyglucose F18 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05286801 2026-03-18

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡